-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hengrui Pharmaceuticals innovative drug SHR6390 tablets were included in the list of proposed breakthrough treatments by the Drug Evaluation Center of the National Medical Products Administration.
Source: CDE
SHR6390 is an oral, high-efficiency and selective small molecule CDK4/6 inhibitor developed by Jiangsu Hengrui, which belongs to the first class of chemical drugs.
Introduction to CDK4/6 Inhibitors
Introduction to CDK4/6 InhibitorsCyclin Dependent Kinase (CDK) is a key kinase involved in cell cycle regulation.
CDK4/6 inhibitor approval status
CDK4/6 inhibitor approval statusIn recent years, CDK4/6 inhibitors are rapidly changing the treatment pattern of HR+ and HER2- advanced breast cancer.
Pfizer’s piperacillil no longer leads the way, CDK4/6 inhibitor melee is about to start
Pfizer’s piperacillil no longer leads the way, CDK4/6 inhibitor melee is about to startAs the first CDK4/6 inhibitor drug to be marketed, Pfizer's piperacillil has an obvious first-mover advantage.
It can be said that piperacillil dominates the CDK4/6 inhibitor market, and even if reboxilil and abecilil are listed afterwards, they have not been able to shake its market position.
In fact, on December 18, 2020, Qilu Pharmaceutical's 4 generic drugs, piperacillil capsules, have been approved for marketing by NMPA, which is the first imitation of this variety, and its indication is the first-line combination of aromatase inhibitors for the treatment of postmenopausal patients.
(Source: CDE)
In short, CDK 4/6 is a star target, and many companies are developing innovative drugs in the country.
Reference source:
1.
3.
4.
